⌘K
Loading ticker…
As of 2026-08-24, Pacira BioSciences, Inc. Common Stock (PCRX) has a 3-month relative strength percentile of 61 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 50. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.9%, relative volume 0.48×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
PCRX appears in 1 ETF as of Jun 2026: PSC at 0.10% weight, $2M notional.
Held by 101 ETFs · $294M across latest filings · largest weight 1.90% (XPH).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.10% | $2M | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PCRX Jan avg: 4.36% median: -0.85% win: 50% σ: 25.46% n: 4 2022-04-12 → 2026-07-31 | PCRX Feb avg: -0.60% median: -1.00% win: 50% σ: 9.42% n: 4 2022-04-12 → 2026-07-31 | PCRX Mar avg: 0.17% median: 0.73% win: 50% σ: 3.69% n: 4 2022-04-12 → 2026-07-31 | PCRX Apr avg: 4.74% median: 8.25% win: 80% σ: 9.32% n: 5 2022-04-12 → 2026-07-31 | PCRX May avg: -5.71% median: -8.91% win: 20% σ: 12.86% n: 5 2022-04-12 → 2026-07-31 | PCRX Jun avg: -1.28% median: -5.67% win: 40% σ: 8.00% n: 5 2022-04-12 → 2026-07-31 | PCRX Jul avg: -9.55% median: -9.28% win: 20% σ: 11.92% n: 5 2022-04-12 → 2026-07-31 | PCRX Aug avg: -2.07% median: -5.05% win: 25% σ: 21.22% n: 4 2022-04-12 → 2026-07-31 (current) | PCRX Sep avg: -4.60% median: -3.33% win: 25% σ: 6.08% n: 4 2022-04-12 → 2026-07-31 | PCRX Oct avg: -4.33% median: -5.29% win: 25% σ: 11.41% n: 4 2022-04-12 → 2026-07-31 | PCRX Nov avg: 0.46% median: -0.80% win: 50% σ: 7.43% n: 4 2022-04-12 → 2026-07-31 | PCRX Dec avg: 6.23% median: 10.61% win: 75% σ: 18.54% n: 4 2022-04-12 → 2026-07-31 |